

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

ELECTION OF THE EMPLOYEE REPRESENTATIVE SUPERVISOR

麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”) hereby announces that Mr. Wang Maolin (汪卯林先生), the existing Company’s employee representative supervisor of the 8th session of the Supervisory Committee of the Company, was re-elected as the employee representative supervisor of the 9th session of the Supervisory Committee of the Company at the meeting of the employees’ representatives held on 23 June 2017. The other two shareholder representative supervisors of the 9th session of the Supervisory Committee of the Company have been elected at the 2016 annual general meeting of the Company held on 23 June 2017 (the “**AGM**”). The two shareholder representative supervisors re-elected at the AGM, namely Mr. Huang Huamin (黃華敏先生) and Mr. Tang Yin (湯胤先生), together with Mr. Wang Maolin, the employee representative supervisor, will constitute the 9th session of the Supervisory Committee of the Company.

Pursuant to the disclosure requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”), the biographical details of Mr. Wang Maolin are as follows:

Mr. Wang Maolin (汪卯林先生), aged 51, graduated from the Law Department of Anhui University (安徽大學) and was awarded with a bachelor’s degree in Law. From January 2001 to present, Mr. Wang has been our Chief Supervisor of the legal supervision head office. Mr. Wang has been the chairman of our labour union and the employee representative supervisor of our Supervisory Committee from January 2010 to present. In January 2012, Mr. Wang was elected as a representative of 8th Zhuhai

People's Congress (珠海市第八屆人民代表大會). Mr. Wang has served as the deputy chairman of the Zhuhai Committee of Jiusan Society (九三學社珠海市委員會) from July 2016 to present and representative of 9th Zhuhai People's Congress (珠海市第九屆人民代表大會) from January 2017 to present. He has served as the Chief Supervisor of our Supervisory Committee since June 2014 to present.

The term of office of Mr. Wang Maolin as the employee representative supervisor is three years, commencing from 30 June 2017 upon the passing of the relevant resolutions in relation to the re-election of the supervisors of the 9th session of the Supervisory Committee of the Company at the AGM and up to the expiration date of the term of the 9th session of Supervisory Committee of the Company. The Company will enter into a service agreement with Mr. Wang Maolin for a period in line with the term of the 9th session of the Supervisory Committee of the Company. During his term of office, Mr. Wang Maolin will be offered a supervisor monthly allowance of RMB3,500 plus a basic salary and an annual performance bonus which are determined in accordance with the Company's relevant remuneration policy.

Mr. Wang Maolin does not have any relationships with the directors, other supervisors, senior management, substantial shareholders or controlling shareholders of the Company, nor does he have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). He has not held any directorships or supervisorships in other Hong Kong and overseas listed companies at present and in the past three years.

Save as disclosed in this announcement, there is no other information in relation to Mr. Wang Maolin required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

By order of the Board

Livzon Pharmaceutical Group Inc. *

麗珠醫藥集團股份有限公司

Yang Liang

Company Secretary

Zhuhai, China

23 June 2017

As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Yang Daihong (Vice President); the Non-executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Qiu Qingfeng and Mr. Zhong Shan; and the Independent Non-executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.

** For identification purpose only*